Judge Won't Subject All Fosamax MDL Claims To Lone Pine

Law360, New York (November 21, 2012, 6:36 PM EST) -- The New York federal judge overseeing multidistrict litigation that includes more than 950 suits alleging Merck &. Co. Inc.'s osteoporosis drug Fosamax causes jaw deterioration granted a so-called Lone Pine order on Tuesday requiring some plaintiffs to support their claims with expert reports.

Merck had asked the court to require the additional causation theory and evidence necessary under the Lone Pine standard for all of the cases, but U.S. District Judge John F. Keenan said it should only apply to those allegation that did not involve...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.